California State Teachers Retirement System decreased its position in Puma Biotechnology Inc (NASDAQ:PBYI) by 9.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 45,990 shares of the biopharmaceutical company’s stock after selling 4,903 shares during the period. California State Teachers Retirement System owned about 0.12% of Puma Biotechnology worth $5,507,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of PBYI. Russell Investments Group Ltd. purchased a new stake in shares of Puma Biotechnology in the second quarter valued at about $2,026,000. Strs Ohio purchased a new stake in shares of Puma Biotechnology in the second quarter valued at about $122,000. Schwab Charles Investment Management Inc. boosted its holdings in shares of Puma Biotechnology by 3.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 123,380 shares of the biopharmaceutical company’s stock valued at $10,784,000 after acquiring an additional 4,068 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Puma Biotechnology by 0.8% in the second quarter. Rhumbline Advisers now owns 33,733 shares of the biopharmaceutical company’s stock valued at $2,948,000 after acquiring an additional 271 shares in the last quarter. Finally, State of Wisconsin Investment Board purchased a new stake in shares of Puma Biotechnology in the second quarter valued at about $1,923,000. 96.00% of the stock is currently owned by institutional investors and hedge funds.
Several analysts have recently weighed in on PBYI shares. Bank of America reaffirmed a “buy” rating and issued a $135.00 target price (up previously from $117.00) on shares of Puma Biotechnology in a report on Monday, October 9th. Citigroup reaffirmed a “buy” rating and issued a $156.00 target price (up previously from $114.00) on shares of Puma Biotechnology in a report on Thursday, October 5th. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $131.00 target price on shares of Puma Biotechnology in a report on Wednesday, October 4th. BidaskClub raised shares of Puma Biotechnology from a “hold” rating to a “buy” rating in a report on Friday, September 8th. Finally, Stifel Nicolaus lifted their target price on shares of Puma Biotechnology from $110.00 to $130.00 and gave the company a “buy” rating in a report on Monday, October 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. Puma Biotechnology presently has an average rating of “Buy” and a consensus price target of $130.67.
Shares of Puma Biotechnology Inc (NASDAQ PBYI) opened at $98.85 on Tuesday. The company has a market cap of $3,750.00, a PE ratio of -12.07 and a beta of 0.73. Puma Biotechnology Inc has a fifty-two week low of $28.35 and a fifty-two week high of $136.90.
Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($2.07) EPS for the quarter, topping analysts’ consensus estimates of ($2.50) by $0.43. The company had revenue of $6.10 million for the quarter, compared to analysts’ expectations of $3.78 million. During the same period in the prior year, the firm posted ($1.11) EPS. analysts anticipate that Puma Biotechnology Inc will post -8.19 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://sportsperspectives.com/2018/01/02/california-state-teachers-retirement-system-sells-4903-shares-of-puma-biotechnology-inc-pbyi.html.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.